Regulatory Guide
Understanding Compounded vs Research Peptides
A clear explanation of compounded peptides versus research peptides, including prescriptions, 503A/503B pharmacies, and why the distinction matters.
Two Different Product Categories
Compounded peptides and research peptides are not interchangeable labels for the same thing. They belong to different regulatory categories, are produced under different operating models, and are intended for different end users.
Compounded peptides are prepared by compounding pharmacies under a prescription framework for individual patients or office-use supply, depending on the pharmacy model. Research peptides are sold for laboratory research and are not represented as patient-ready therapies.
How the Pharmacy Framework Differs
Compounding pharmacies operate under sections such as 503A and 503B of the FD&C Act. Their products are tied to patient prescriptions, sterile-compounding rules, pharmacy oversight, and human-use intent. Research suppliers do not operate under that same patient-care model.
That is why a prescription is relevant in a compounding context but irrelevant in a research-chemical context. The product category itself is different.
Why the Distinction Matters
Confusing these two categories creates compliance problems. A research vendor should not imply that a physician can simply prescribe its catalog. A compounding pharmacy should not market itself as if it were just a general research-chemical storefront.
OSYRIS sits firmly in the research category. We do not require prescriptions, and we do not sell compounded pharmaceuticals.
Featured Links
Review the OSYRIS testing workflow, documentation practices, and quality standards that support each batch.
Open → Regulatory Guide Research Use Only ExplainedSee how RUO positioning differs from pharmacy and drug-distribution frameworks.
Read → Regulatory Guide Are Research Peptides Legal in the United States?Use the legality overview as the broader federal context for this compounded-vs-research distinction.
Read →Questions
Common Questions
Can OSYRIS peptides be prescribed?
No. OSYRIS products are sold as research compounds, not as prescription pharmaceuticals.
What is a 503B pharmacy?
A 503B outsourcing facility is a compounding operation regulated under a specific human-use pharmacy framework for office-use sterile products.
Is compounding legal?
Yes, within the compounding framework and subject to the rules that govern compounding pharmacies. It is a different regulatory lane than research-chemical sales.
Are compounded peptides FDA-approved?
Compounded products are not the same thing as FDA-approved branded drugs, though they may be prepared under regulated pharmacy frameworks.
Why is this distinction important?
Because intended use, labeling, prescription status, and regulatory oversight all change depending on whether the product is compounded or sold for research.
How does the FDA regulate compounding vs research?
Compounding is governed through pharmacy and FD&C Act pathways tied to human-use preparation. Research products are governed through their RUO status, labeling, and truthful non-therapeutic marketing.
